Primary pineal tumors: Outcome and prognostic factors\-a study from the Rare Cancer Network (RCN)

Salvador Villà, Robert C. Miller, Marco Krengli, Huda Abusaris, Brigitta G. Baumert, Stephanie Servagi-Vernat, Sefik Igdem, Anna Lucas, Susanna Boluda, René O. Mirimanoff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose To better define outcome and prognostic factors in primary pineal tumors. Materials and methods Thirty-five consecutive patients from seven academic centers of the Rare Cancer Network diagnosed between 1988 and 2006 were included. Median age was 36 years. Surgical resection consisted of biopsy in 12 cases and resection in 21 (2 cases with unknown resection). All patients underwent radiotherapy and 12 patients received also chemotherapy. Results Histological subtypes were pineoblastoma (PNB) in 21 patients, pineocytoma (PC) in 8 patients and pineocytoma with intermediate differentiation in 6 patients. Six patients with PNB had evidence of spinal seeding. Fifteen patients relapsed (14 PNB and 1 PC) with PNB cases at higher risk (p = 0.031). Median survival time was not reached. Median disease-free survival was 82 months (CI 50 % 28-275). In univariate analysis, age younger than 36 years was an unfavorable prognostic factor (p = 0.003). Patients with metastases at diagnosis had poorer survival (p = 0.048). Late side effects related to radiotherapy were dementia, leukoencephalopathy or memory loss in seven cases, occipital ischemia in one, and grade 3 seizures in two cases. Side effects related to chemotherapy were grade 3-4 leucopenia in five cases, grade 4 thrombocytopenia in three cases, grade 2 anemia in two cases, grade 4 pancytopenia in one case, grade 4 vomiting in one case and renal failure in one case. Conclusions Age and dissemination at diagnosis influenced survival in our series. The prevalence of chronic toxicity suggests that new adjuvant strategies are advisable.

Original languageEnglish (US)
Pages (from-to)827-834
Number of pages8
JournalClinical and Translational Oncology
Volume14
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Pinealoma
Neoplasms
Survival
Radiotherapy
Leukoencephalopathies
Drug Therapy
Pancytopenia
Memory Disorders
Leukopenia
Disease-Free Survival
Vomiting
Renal Insufficiency
Dementia
Anemia
Seizures
Ischemia
Neoplasm Metastasis
Biopsy

Keywords

  • Primary pineal tumors
  • Prognostic factors
  • Rare Cancer Network

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Villà, S., Miller, R. C., Krengli, M., Abusaris, H., Baumert, B. G., Servagi-Vernat, S., ... Mirimanoff, R. O. (2012). Primary pineal tumors: Outcome and prognostic factors\-a study from the Rare Cancer Network (RCN). Clinical and Translational Oncology, 14(11), 827-834. https://doi.org/10.1007/s12094-012-0869-0

Primary pineal tumors : Outcome and prognostic factors\-a study from the Rare Cancer Network (RCN). / Villà, Salvador; Miller, Robert C.; Krengli, Marco; Abusaris, Huda; Baumert, Brigitta G.; Servagi-Vernat, Stephanie; Igdem, Sefik; Lucas, Anna; Boluda, Susanna; Mirimanoff, René O.

In: Clinical and Translational Oncology, Vol. 14, No. 11, 11.2012, p. 827-834.

Research output: Contribution to journalArticle

Villà, S, Miller, RC, Krengli, M, Abusaris, H, Baumert, BG, Servagi-Vernat, S, Igdem, S, Lucas, A, Boluda, S & Mirimanoff, RO 2012, 'Primary pineal tumors: Outcome and prognostic factors\-a study from the Rare Cancer Network (RCN)', Clinical and Translational Oncology, vol. 14, no. 11, pp. 827-834. https://doi.org/10.1007/s12094-012-0869-0
Villà, Salvador ; Miller, Robert C. ; Krengli, Marco ; Abusaris, Huda ; Baumert, Brigitta G. ; Servagi-Vernat, Stephanie ; Igdem, Sefik ; Lucas, Anna ; Boluda, Susanna ; Mirimanoff, René O. / Primary pineal tumors : Outcome and prognostic factors\-a study from the Rare Cancer Network (RCN). In: Clinical and Translational Oncology. 2012 ; Vol. 14, No. 11. pp. 827-834.
@article{6b7a4a69cd754836aae71d41347a22b9,
title = "Primary pineal tumors: Outcome and prognostic factors\-a study from the Rare Cancer Network (RCN)",
abstract = "Purpose To better define outcome and prognostic factors in primary pineal tumors. Materials and methods Thirty-five consecutive patients from seven academic centers of the Rare Cancer Network diagnosed between 1988 and 2006 were included. Median age was 36 years. Surgical resection consisted of biopsy in 12 cases and resection in 21 (2 cases with unknown resection). All patients underwent radiotherapy and 12 patients received also chemotherapy. Results Histological subtypes were pineoblastoma (PNB) in 21 patients, pineocytoma (PC) in 8 patients and pineocytoma with intermediate differentiation in 6 patients. Six patients with PNB had evidence of spinal seeding. Fifteen patients relapsed (14 PNB and 1 PC) with PNB cases at higher risk (p = 0.031). Median survival time was not reached. Median disease-free survival was 82 months (CI 50 {\%} 28-275). In univariate analysis, age younger than 36 years was an unfavorable prognostic factor (p = 0.003). Patients with metastases at diagnosis had poorer survival (p = 0.048). Late side effects related to radiotherapy were dementia, leukoencephalopathy or memory loss in seven cases, occipital ischemia in one, and grade 3 seizures in two cases. Side effects related to chemotherapy were grade 3-4 leucopenia in five cases, grade 4 thrombocytopenia in three cases, grade 2 anemia in two cases, grade 4 pancytopenia in one case, grade 4 vomiting in one case and renal failure in one case. Conclusions Age and dissemination at diagnosis influenced survival in our series. The prevalence of chronic toxicity suggests that new adjuvant strategies are advisable.",
keywords = "Primary pineal tumors, Prognostic factors, Rare Cancer Network",
author = "Salvador Vill{\`a} and Miller, {Robert C.} and Marco Krengli and Huda Abusaris and Baumert, {Brigitta G.} and Stephanie Servagi-Vernat and Sefik Igdem and Anna Lucas and Susanna Boluda and Mirimanoff, {Ren{\'e} O.}",
year = "2012",
month = "11",
doi = "10.1007/s12094-012-0869-0",
language = "English (US)",
volume = "14",
pages = "827--834",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "11",

}

TY - JOUR

T1 - Primary pineal tumors

T2 - Outcome and prognostic factors\-a study from the Rare Cancer Network (RCN)

AU - Villà, Salvador

AU - Miller, Robert C.

AU - Krengli, Marco

AU - Abusaris, Huda

AU - Baumert, Brigitta G.

AU - Servagi-Vernat, Stephanie

AU - Igdem, Sefik

AU - Lucas, Anna

AU - Boluda, Susanna

AU - Mirimanoff, René O.

PY - 2012/11

Y1 - 2012/11

N2 - Purpose To better define outcome and prognostic factors in primary pineal tumors. Materials and methods Thirty-five consecutive patients from seven academic centers of the Rare Cancer Network diagnosed between 1988 and 2006 were included. Median age was 36 years. Surgical resection consisted of biopsy in 12 cases and resection in 21 (2 cases with unknown resection). All patients underwent radiotherapy and 12 patients received also chemotherapy. Results Histological subtypes were pineoblastoma (PNB) in 21 patients, pineocytoma (PC) in 8 patients and pineocytoma with intermediate differentiation in 6 patients. Six patients with PNB had evidence of spinal seeding. Fifteen patients relapsed (14 PNB and 1 PC) with PNB cases at higher risk (p = 0.031). Median survival time was not reached. Median disease-free survival was 82 months (CI 50 % 28-275). In univariate analysis, age younger than 36 years was an unfavorable prognostic factor (p = 0.003). Patients with metastases at diagnosis had poorer survival (p = 0.048). Late side effects related to radiotherapy were dementia, leukoencephalopathy or memory loss in seven cases, occipital ischemia in one, and grade 3 seizures in two cases. Side effects related to chemotherapy were grade 3-4 leucopenia in five cases, grade 4 thrombocytopenia in three cases, grade 2 anemia in two cases, grade 4 pancytopenia in one case, grade 4 vomiting in one case and renal failure in one case. Conclusions Age and dissemination at diagnosis influenced survival in our series. The prevalence of chronic toxicity suggests that new adjuvant strategies are advisable.

AB - Purpose To better define outcome and prognostic factors in primary pineal tumors. Materials and methods Thirty-five consecutive patients from seven academic centers of the Rare Cancer Network diagnosed between 1988 and 2006 were included. Median age was 36 years. Surgical resection consisted of biopsy in 12 cases and resection in 21 (2 cases with unknown resection). All patients underwent radiotherapy and 12 patients received also chemotherapy. Results Histological subtypes were pineoblastoma (PNB) in 21 patients, pineocytoma (PC) in 8 patients and pineocytoma with intermediate differentiation in 6 patients. Six patients with PNB had evidence of spinal seeding. Fifteen patients relapsed (14 PNB and 1 PC) with PNB cases at higher risk (p = 0.031). Median survival time was not reached. Median disease-free survival was 82 months (CI 50 % 28-275). In univariate analysis, age younger than 36 years was an unfavorable prognostic factor (p = 0.003). Patients with metastases at diagnosis had poorer survival (p = 0.048). Late side effects related to radiotherapy were dementia, leukoencephalopathy or memory loss in seven cases, occipital ischemia in one, and grade 3 seizures in two cases. Side effects related to chemotherapy were grade 3-4 leucopenia in five cases, grade 4 thrombocytopenia in three cases, grade 2 anemia in two cases, grade 4 pancytopenia in one case, grade 4 vomiting in one case and renal failure in one case. Conclusions Age and dissemination at diagnosis influenced survival in our series. The prevalence of chronic toxicity suggests that new adjuvant strategies are advisable.

KW - Primary pineal tumors

KW - Prognostic factors

KW - Rare Cancer Network

UR - http://www.scopus.com/inward/record.url?scp=84871217955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871217955&partnerID=8YFLogxK

U2 - 10.1007/s12094-012-0869-0

DO - 10.1007/s12094-012-0869-0

M3 - Article

C2 - 22914906

AN - SCOPUS:84871217955

VL - 14

SP - 827

EP - 834

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 11

ER -